The goal of the Clinical Research Core is identify, recruit, and consent patients with glioma to provide investigators in the SPORE high quality biospecimens and corollary demographic and clinical data, and to make these resources available for future studies.
The specific aims are:
Specific Aim 1 : To identify, recruit, and consent all glioma patients for participation in observational human studies, and for use of brain tumor tissue for multiple purposes outlined by the Cores and Projects; to obtain demographic and clinical data from patient records and enter the data into the Mayo Clinic Neuro-Oncology Database;
Specific Aim 2 : To coordinate the collection of normal tissue biospecimens including blood, saliva, and urine;
Specific Aim 3 : To screen, consent, and enroll all patients for participation in therapeutic clinical trials, provide quality control for administration of protocol-specific therapy, collect and enter protocol-specific clinical data prospectively, report adverse events, and schedule all visits, tests, consultations, and therapies for patients enrolled in therapeutic clinical trials;
Specific Aim 4 : To provide consultation in development and implementation of observational and therapeutic clinical trials, including oversight of compliance with regulatory issues involving human subjects This core will serve as the interface with Mayo Clinic Cancer Center's shared resources including the Biospecimens Acquisition and Processing shared resource, the Clinical Research Office, and the Protocol Review and Monitoring System, as well as the institutional Clinical Research Unit supported by the Mayo Clinic Center for Translational Science Activities (CTSA) award. In addition, this core will interact with the other cores of this SPORE application, including the Administrative Core by participating as a member of the Executive Committee, with the Animal Core by obtaining patient consent for use of brain tumor tissue for mouse xenografts, with the Biostatistics Core by joint development of data entry forms and quality assurance of clinical data, and with the Pathology and Tissue Procurement Core by sharing the responsibilities for consent for and collection of biospecimens. These essential services provide support for Project 1, specific aim 3; Project 2, specific aim 4; Project 4, specific aims 1B, 2A and 2B; the Animal, Biospecimen and Tissue Procurement, the Biostatistics Cores; and the Career Development and Developmental Research Programs. Core utilization will include assisting in the recruitment of patients to studies, ensuring eligibility, informed consent, scheduling appropriate protocol tests and follow-up, obtaining clinical data and biospecimens from patients enrolled in clinical trials, entry of clinical trials data information according to Mayo Clinic Cancer Center policy set forth by the Clinical Research Office and Protocol Review and Monitoring System, and compliance with human subjects protection in keeping with the policies of the Mayo Clinic Cancer Center. Finally, this core will interface with the clinical research components of other Brain Tumor SPORE grantees, cancer centers and multi-center groups to facilitate multi-Institutional clinical research arising out of national brain tumor research efforts.

Public Health Relevance

The goal of the Clinical Research Core is to provide Investigators in the SPORE high quality biospecimens as well as patient data from consented patients with glioma and to make these resources available for future studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108961-07
Application #
8555430
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Project Start
2004-09-20
Project End
2016-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
7
Fiscal Year
2012
Total Cost
$132,159
Indirect Cost
$59,162
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Hardcastle, Jayson; Mills, Lisa; Malo, Courtney S et al. (2017) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol 19:493-502
Robinson, Steven; Galanis, Evanthia (2017) Potential and clinical translation of oncolytic measles viruses. Expert Opin Biol Ther 17:353-363
Kurokawa, C; Geekiyanage, H; Allen, C et al. (2017) Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J Neurooncol 131:41-48
Kizilbash, Sani H; Gupta, Shiv K; Chang, Kenneth et al. (2017) Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther 16:2735-2746
Melin, Beatrice S; Barnholtz-Sloan, Jill S; Wrensch, Margaret R et al. (2017) Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet 49:789-794
Yin, Xueqian; Kang, Jeong-Han; Andrianifahanana, Mahefatiana et al. (2017) Basolateral delivery of the type I transforming growth factor beta receptor is mediated by a dominant-acting cytoplasmic motif. Mol Biol Cell 28:2701-2711
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2017) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets :
Heim, Joel B; Squirewell, Edwin J; Neu, Ancilla et al. (2017) Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix. Proc Natl Acad Sci U S A 114:3933-3938
Tivnan, Amanda; Heilinger, Tatjana; Ramsey, Joanne M et al. (2017) Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget 8:16605-16620
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016

Showing the most recent 10 out of 243 publications